Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant HIPEC for Resectable Pancreatic Adenocarcinoma
NCT02850874Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Wake Forest University Health Sciences. Planned start Feb 2016; status: withdrawn.
02
Drugs
gemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02850874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02850874.